Acrivon Therapeutics Announces Positive Acr-368 Phase 2B Endometrial Cancer Clinical Data With EU Expansion to Accelerate Enrollment, Initial Acr-2316 Clinical Data, and Acr-6840, Its Next AP3-Enabled Development Candidate, Targeting Cdk11

THOMSON REUTERS
Jan 08

Acrivon Therapeutics Announces Positive Acr-368 Phase 2B Endometrial Cancer Clinical Data With EU Expansion to Accelerate Enrollment, Initial Acr-2316 Clinical Data, and Acr-6840, Its Next AP3-Enabled Development Candidate, Targeting Cdk11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10